ATROPINE SULFATE- atropine sulfate ointment
Bausch & Lomb Incorporated
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been
approved by FDA. For further information about unapproved drugs, click here.
Ophthalmic Ointment, 1% (Sterile)
Atropine Sulfate Ophthalmic Ointment, 1% is a sterile topical anticholinergic for ophthalmic use. The
active ingredient is represented by the chemical structural formula:
H NO ) H SO H O
Mol. Wt. 694.83
Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-[3.2.1]oct-3-yl ester, endo-(±)-, sulfate
(2:1) (salt), monohydrate.
Each gram contains:
ACTIVE: Atropine Sulfate, 1% (10 mg); INACTIVES: Lanolin oil, mineral oil, purified water, and
The anticholinergic effect of this product blocks the responses of the sphincter muscle of the iris and
the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation
(mydriasis) and paralysis of accommodation (cycloplegia).
INDICATIONS AND USAGE
For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in
inflammatory conditions of the iris and uveal tract.
This product should not be used in patients with primary glaucoma or a predisposition to narrow
anterior chamber angle glaucoma.
This product should not be used in pediatric patients who have previously had a severe systemic
reaction to atropine. This product should not be used in those persons showing hypersensitivity to any
component of this preparation.
In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain
individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic
symptoms of atropine poisoning. If this occurs, discontinue medication and use appropriate therapy as
outlined in OVERDOSAGE.
To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for
two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the
depth of the angle of the anterior chamber should be made. Administration of atropine in infants requires
Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated.
Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.
Parents should be warned not to get this preparation in their children’s mouth and to wash their own
hands and the child’s hands following administration.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
No studies have been conducted in animals or in humans to evaluate the potential of these effects.
Animal reproduction studies have not been performed with atropine. It is also not known whether
atropine can cause fetal harm when administered to a pregnant woman or can affect reproduction
capacity. Atropine should be given to pregnant women only if clearly needed.
See CONTRAINDICATIONS and WARNINGS.
Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular
congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by
hypotension with progressive respiratory depression. Coma and death have been reported in the very
To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant
Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or
Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in
pediatric patients), blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants,
mental aberration (hallucinosis) and loss of neuromuscular coordination.
Atropine poisoning, although distressing, is rarely fatal, even with large doses of atropine, and is self-
limited if the cause is recognized and the atropine medication is discontinued. In severe intoxication,
physostigmine salicylate may be administered parenterally to provide more prompt relief of the
intoxication. Give physostigmine salicylate as 1-5 mL IV of dilution containing 1 mg in 5 mL of saline.
The smaller dose is for pediatric patients, and injection should take not less than 2 minutes. EKG control
is advisable. Dosage can be repeated every 5 minutes up to a total dose of 2 mg in pediatric patients and
6 mg in adults every 30 minutes. Physostigmine is contraindicated in hypotensive reactions. Atropine (1
mg) should be available for immediate injection if physostigmine causes bradycardia, convulsions or
bronchoconstriction. In pediatric patients, the body surface must be kept moist.
Use extreme caution when employing short-acting barbiturates to control excitement.
DOSAGE AND ADMINISTRATION
Apply a small amount of ointment to the conjunctival sac once or twice a day, or as directed by a
FOR OPHTHALMIC USE ONLY
Atropine Sulfate Ophthalmic Ointment, 1% is supplied in an ophthalmic tip applicator tube in the
3.5 g tubes – NDC 24208-825-55
Store between 15°-25°C (59°-77°F).
KEEP OUT OF REACH OF CHILDREN
Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
©Bausch & Lomb Incorporated
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
FOR OPHTALMIC USE ONLY
Net. Wt. 1/8 oz. (3.5g)
BAUSCH + LOMB
Bausch & Lomb Incorporated
atropine sulfate ointment
Product T ype
HUMAN PRESCRIPTION DRUG
Ite m Code (Source )
NDC:2420 8 -8 25
Route of Administration
Active Ingredient/Active Moiety
Basis of Strength
Stre ng th
ATRO PINE SULFATE (UNII: 0 3J5ZE7KA5) (ATROPINE - UNII:7C0 6 9 7DR9 I)
10 mg in 1 g
Stre ng th
LANO LIN O IL (UNII: OVV5IIJ58 F)
MINERAL O IL (UNII: T5L8 T28 FGP)
WATER (UNII: 0 59 QF0 KO0 R)
PETRO LATUM (UNII: 4T6 H12BN9 U)
Marketing Start Date
Marketing End Date
NDC:2420 8 -8 25-55
1 in 1 CARTON
0 9 /30 /19 9 0
3.5 g in 1 TUBE; Type 0 : No t a Co mbinatio n Pro duct
Marke ting Cate gory
Application Numbe r or Monograph Citation
Marke ting Start Date
Marke ting End Date
Unappro ved drug o ther
0 9 /30 /19 9 0
Bausch & Lomb Incorporated (196603781)
Ad d re s s
Busine ss Ope rations
Bausch & Lo mb Inco rpo rated
0 79 58 76 25
MANUFACTURE(2420 8 -8 25) , LABEL(2420 8 -8 25) , PACK(2420 8 -8 25)